Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK (2025)
Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50
ESMO Open, 10 (5), 105073 (in press)
DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908

Grønberg BH, Killingberg KT, Fløtten Ø, Bjaanæs MM, Brustugun OT, Madebo T, Langer SW, Risumlund SL, Schytte T, Helbekkmo N, Neumann K, Yksnøy Ø, Engleson J, Fluge S, Naustdal T, Giske LE, Nyman J, Tsakonas G, Halvorsen TO (2025)
High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial
J Thorac Oncol (in press)
DOI 10.1016/j.jtho.2025.04.007, PubMed 40258573

Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT, Grønberg BH (2025)
Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study
Front Oncol, 15, 1595028
DOI 10.3389/fonc.2025.1595028, PubMed 40206591